GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioMarin Pharmaceutical BMRN · USD

Health Care · US listing · 🇺🇸 United States

Compare

57.18

+2.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.22bn

FY2016FY2025

Net income

$348.9m

FY2016FY2025

Free cash flow

$725.0m

FY2016FY2025

Shareholders' equity

$6.09bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$3.22bn$2.85bn$2.42bn$2.10bn$1.85bn$1.86bn$1.70bn$1.49bn$1.31bn$1.12bn
Gross profit$2.48bn$2.27bn$1.89bn$1.59bn$1.38bn$1.34bn$1.34bn$1.18bn$1.07bn$907.2m
Research and development$921.9m$747.2m$746.8m$649.6m$628.8m$628.1m$715.0m$696.3m$610.8m$661.9m
Operating income$533.5m$484.2m$185.8m$161.0m−$82.3m−$36.3m−$94.1m−$121.9m−$8.0m−$794.9m
Net income$348.9m$426.9m$167.6m$141.6m−$64.1m$854.0m−$23.8m−$77.2m−$117.0m−$630.2m
Diluted earnings per share1.772.170.870.76-0.354.63-0.13-0.43-0.67-3.66

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$7.59bn$6.99bn$6.84bn$6.38bn$6.00bn$5.85bn$4.69bn$4.43bn$4.63bn$4.02bn
Cash and short-term investments$1.56bn$1.14bn$1.07bn$1.29bn$1.01bn$1.07bn$753.8m$1.08bn$1.40bn$789.7m
Total liabilities$1.51bn$1.33bn$1.89bn$1.77bn$1.73bn$1.74bn$1.57bn$1.46bn$1.82bn$1.26bn
Debt$597.7m$596.2m$1.09bn$1.09bn$1.08bn$1.08bn$858.1m$830.4m$1.17bn$683.2m
Shareholders' equity$6.09bn$5.66bn$4.95bn$4.60bn$4.27bn$4.11bn$3.12bn$2.97bn$2.81bn$2.77bn
Shares outstanding197m197m192m186m184m184m182m178m176m172m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$828.0m$572.8m$159.3m$175.9m$304.5m$85.4m$48.3m$20.2m−$8.8m−$227.8m
Capital spending−$103.0m−$97.4m−$107.6m−$121.0m−$119.2m−$137.5m−$145.0m−$144.6m−$199.2m−$148.4m
Free cash flow$725.0m$475.4m$51.6m$54.9m$185.3m−$52.2m−$96.8m−$124.4m−$208.0m−$376.2m
Dividends paid———−$15.1m−$3.4m−$71.9m−$11.1m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$989.7m$766.2m$874.6m$776.1m$825.4m$745.1m$747.3m$745.7m
Gross profit$786.9m$571.2m$579.5m$636.0m$675.3m$593.6m$611.2m$557.3m
Operating income$124.7m$129.6m$79.4m−$46.7m$276.9m$223.9m$161.4m$113.9m
Net income$44.8m$105.5m−$46.6m−$30.7m$240.5m$185.7m$124.9m$106.1m
Diluted earnings per share0.230.54-0.24-0.161.220.940.640.54
Cash from operations$168.0m$220.0m$99.0m$368.0m$185.0m$174.0m$185.0m$221.0m
Capital spending−$28.0m−$20.0m−$40.0m−$33.0m−$17.0m−$16.0m−$20.0m−$21.0m
Free cash flow$140.0m$200.0m$59.0m$335.0m$168.0m$158.0m$165.0m$200.0m
Total assets$11.72bn$8.59bn$7.59bn$7.61bn$7.46bn$7.15bn$6.99bn$6.85bn
Cash and short-term investments$874.0m$2.22bn$1.56bn$1.48bn$1.43bn$1.27bn$1.14bn$930.4m
Debt$4.20bn$1.44bn$605.9m$604.2m$603.9m$602.0m$602.7m$602.7m
Shareholders' equity$6.32bn$6.21bn$6.09bn$6.06bn$6.03bn$5.79bn$5.66bn$5.41bn

Financial ratios

Data as of 5 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin77.1%79.7%78.0%76.0%74.5%71.8%
Operating margin16.6%17.0%7.7%7.7%-4.5%-2.0%
Net margin10.8%15.0%6.9%6.8%-3.5%45.9%
Return on equity5.7%7.5%3.4%3.1%-1.5%20.8%
Return on assets4.6%6.1%2.5%2.2%-1.1%14.6%
Free cash flow yield8.2%6.0%2.4%2.8%4.0%2.1%
Revenue growth12.9%18.0%15.4%13.5%-0.8%9.2%
Earnings growth-18.3%154.6%18.4%-320.9%-107.5%-3681.1%
Current ratio5.21x5.33x2.51x4.67x4.21x4.76x
Debt to equity0.10x0.11x0.22x0.24x0.26x0.26x
Equity ratio80.2%81.0%72.4%72.2%71.1%70.2%
Interest coverage48.95x38.23x10.72x10.08x-5.37x-1.24x
R&D as a share of sales28.6%26.2%30.9%31.0%34.1%33.8%
Buybacks as a share of market value-0.4%-2.5%-3.1%-1.3%0.5%-1.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue15.4%11.6%13.7%
Operating income49.1%——
Net income35.1%-16.4%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin78.3%77.8%76.6%77.8%
Operating margin16.8%12.9%8.7%0.6%
Net margin12.8%10.2%13.1%4.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings33.630.3110.3136.0-253.118.9-418.6-127.2-86.6-14.7
Price to sales3.64.57.79.28.88.75.96.67.78.3

Market value over time

30 Nov 2016 to 2 Oct 2026, in USD

$14.39bn$11.10bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-20%-33%-9%23%-1%60%-1%-6%7%-19%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.